Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-07), Santen Pharmaceutical Co's 3-1 Month Momentum % is 18.74%.
The industry rank for Santen Pharmaceutical Co's 3-1 Month Momentum % or its related term are showing as below:
SNPHF's 3-1 Month Momentum % is ranked better than 94.01% of 1019
companies
in the Drug Manufacturers industry
Industry Median: -6.55
vs SNPHF: 18.74
Santen Pharmaceutical Co (OTCPK:SNPHF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Santen Pharmaceutical Co 3-1 Month Momentum % Related Terms
SNPHF vs LLY, JNJ, ABBV: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santen Pharmaceutical Co 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Santen Pharmaceutical Co's 3-1 Month Momentum % falls into.
Santen Pharmaceutical Co (OTCPK:SNPHF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santen Pharmaceutical Co (SNPHF) has a 3-1 Month Momentum % of 18.74% as of Aug. 07, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Santen Pharmaceutical Co and its competitors. According to the industry distribution chart, Santen Pharmaceutical Co ranks #61 out of 1019 companies in the Drug Manufacturers industry, placing it in the top 6%.
Is Santen Pharmaceutical Co's 3-1 Month Momentum % too high?
Santen Pharmaceutical Co's current 3-1 Month Momentum % is 18.74%. Based on the distribution chart, Santen Pharmaceutical Co ranks #61 out of 1019 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Santen Pharmaceutical Co has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's 3-1 Month Momentum % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Santen Pharmaceutical Co ranks #61 out of 1019 companies for 3-1 Month Momentum %. This places Santen Pharmaceutical Co in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current 3-1 Month Momentum % is 18.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.34, compared to a current price of $13.05 — trading 26.2% above its estimated fair value. The current 3-1 Month Momentum % is 18.74%. Santen Pharmaceutical Co's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current 3-1 Month Momentum % is 18.74% as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued.
The current stock price of $13.05 is trading 26.2% above its estimated GF Value™ of $10.34.
GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SNPHF:
3-1 Month Momentum %: 18.74%
GF Value™: $10.34 vs. price of $13.05 (26.2% above fair value)
No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
71GF Score
Get the complete analysis for SNPHF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNPHF has been successfully added to your 
